curasan AG: New US subsidiary for orthopaedics
curasan AG is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States. The newly founded curasan Inc., with its headquarters in Massachusetts, is responsible for commercial and logistical management as well as marketing activities. This occurs in coordination with the head office in Germany. The processing of orders and shipment is undertaken by specialist service providers, in order to avoid the need to staff such activities locally.
Local sales will occur through an external dealer network that specialises in targeting orthopaedists, trauma surgeons and spine surgeons. For some regions, sales contracts already exist; in the remaining states, the sales network will be expanded during the course of the year.
“Because we have already previously established and successfully disposed of a subsidiary in the US for the dental market, we are now benefiting from that experience”, stated Hans Dieter Rössler, CEO of curasan AG. “At almost US$ 1 billion, the market potential for bone regeneration materials in orthopaedics, trauma surgery and traumatology in the US is extremely attractive. Human bones from tissue banks form the largest proportion of this material; however, the share of synthetic bone replacement materials has clearly risen more sharply than the overall market in the last few years and is predicted to take over the market leadership within the next three years. The aim of our US activities is to participate at a manageable cost in this market development with the synthetic Cerasorb® M Ortho.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
